2024-03-05 08:46:46 ET
- CASI Pharmaceuticals ( Nasdaq: CASI ) shares rose 25% at $6.36 after company and BioInvent International AB ( BINV ) announced preliminary encouraging data for BI-1206 in combination with rituximab in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma in the ongoing development program in China.
- The Phase 1 dose-escalation study showed signs of clinical efficacy, with 4 partial responses and 1 complete response out of 8 evaluable patients.
- The results are consistent with the clinical data that have been previously reported by BioInvent.
- Among the responders in the study being conducted in China, one patient with relapsed Marginal Zone Lymphoma patient who achieved CR has maintained a durable complete remission for 20+ weeks.
- The preliminary results demonstrated a manageable safety profile across all patients.
- Source: Press Release
Read the full article on Seeking Alpha
For further details see:
CASI stock rises on positive interim data from early stage trial for its NHL treatment in China